uveal melanoma (Cancer)
Information
- Disease name
- uveal melanoma
- Disease ID
- DOID:6039
- Description
- "A uveal cancer that has_material_basis_in uvea pigment cells." [url:http\://cancergenome.nih.gov/cancersselected/UvealMelanoma, url:http\://en.wikipedia.org/wiki/Uveal_melanoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03635632 | Active, not recruiting | Phase 1 | C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | April 23, 2019 | December 2039 |
| NCT03417739 | Active, not recruiting | Phase 2 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | March 26, 2018 | August 31, 2025 |
| NCT03070392 | Active, not recruiting | Phase 2 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | October 16, 2017 | June 2025 |
| NCT04364230 | Active, not recruiting | Phase 1/Phase 2 | Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) | September 28, 2020 | May 2025 |
| NCT05542342 | Active, not recruiting | Phase 2 | Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. | September 23, 2022 | May 2024 |
| NCT04417530 | Active, not recruiting | Phase 2 | Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma | August 5, 2020 | May 30, 2025 |
| NCT01983748 | Active, not recruiting | Phase 3 | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma | June 2014 | December 2023 |
| NCT02874040 | Active, not recruiting | N/A | Endoresection of the Tumor Scar or Transpupillary Thermotherapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser) | April 19, 2013 | October 24, 2024 |
| NCT04463368 | Active, not recruiting | Phase 1 | Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases | March 8, 2021 | December 1, 2024 |
| NCT04328844 | Active, not recruiting | Phase 1 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | February 25, 2020 | April 2024 |
| NCT04960891 | Available | A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp | |||
| NCT00121225 | Completed | Phase 2 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | September 2005 | June 2013 |
| NCT02273219 | Completed | Phase 1 | Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | November 19, 2014 | July 2, 2018 |
| NCT02376920 | Completed | 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes | March 2010 | April 2022 | |
| NCT02223819 | Completed | Phase 2 | Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy | March 2015 | July 3, 2019 |
| NCT00351728 | Completed | Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone | June 2006 | August 2012 | |
| NCT00596362 | Completed | N/A | Treatment With Intravitreal Avastin for Large Uveal Melanomas | April 2007 | June 2008 |
| NCT00661622 | Completed | Phase 2 | Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF | October 2004 | June 2012 |
| NCT01034787 | Completed | Phase 2 | Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma | August 17, 2009 | August 8, 2017 |
| NCT01252251 | Completed | Phase 2 | RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma | November 2010 | June 2016 |
| NCT01338389 | Completed | N/A | Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy | June 25, 2012 | June 29, 2017 |
| NCT01430416 | Completed | Phase 1 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | December 20, 2011 | May 22, 2019 |
| NCT01924923 | Completed | New Biopsy Technique for Uveal Melanoma | June 2013 | March 2015 | |
| NCT01955941 | Completed | Vascular Response to Brachytherapy Using Functional OCT | October 2013 | November 22, 2021 | |
| NCT01974752 | Completed | Phase 3 | Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) | April 2014 | October 2016 |
| NCT02517736 | Completed | Phase 2 | Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination | February 2012 | January 13, 2015 |
| NCT02570308 | Completed | Phase 1/Phase 2 | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma | February 29, 2016 | October 17, 2022 |
| NCT02626962 | Completed | Phase 2 | Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | April 2016 | July 22, 2021 |
| NCT02768766 | Completed | Phase 1 | Intermittent Selumetinib for Uveal Melanoma | February 28, 2017 | September 18, 2020 |
| NCT02771340 | Completed | Phase 1 | Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma | May 2016 | September 2017 |
| NCT02843386 | Completed | Phase 3 | Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma | June 23, 2009 | June 12, 2020 |
| NCT02849145 | Completed | N/A | Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) | September 2014 | February 25, 2020 |
| NCT03052127 | Completed | Phase 1/Phase 2 | Study in Subjects With Small Primary Choroidal Melanoma | February 27, 2017 | January 26, 2021 |
| NCT03207347 | Completed | Phase 2 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | August 13, 2018 | August 30, 2022 |
| NCT03297424 | Completed | Phase 1 | A Study of PLX2853 in Advanced Malignancies. | September 12, 2017 | June 7, 2021 |
| NCT03408587 | Completed | Phase 1 | CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) | January 29, 2018 | May 22, 2019 |
| NCT03652077 | Completed | Phase 1 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | September 24, 2018 | August 18, 2021 |
| NCT03712904 | Completed | Phase 2 | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma | August 9, 2019 | December 23, 2022 |
| NCT03922880 | Completed | Phase 1 | Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma | April 16, 2019 | January 20, 2023 |
| NCT04551352 | Completed | Phase 1 | A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas | October 28, 2020 | July 28, 2022 |
| NCT04577742 | Completed | Uveal Melanoma and Brachytheraphy: Long-term Outcomes. | February 1, 2011 | March 30, 2020 | |
| NCT05893654 | Enrolling by invitation | Phase 1/Phase 2 | Melphalan Chemoreduction for Ocular Melanoma | May 1, 2021 | June 2024 |
| NCT06073548 | Not yet recruiting | Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study | October 1, 2023 | April 1, 2026 | |
| NCT06070012 | Not yet recruiting | Phase 2 | Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma | June 30, 2024 | June 30, 2029 |
| NCT05903937 | Not yet recruiting | Phase 1 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases | December 31, 2023 | December 31, 2029 |
| NCT06246149 | Not yet recruiting | Phase 3 | Adjuvant Tebentafusp in High Risk Ocular Melanoma | October 2024 | November 2032 |
| NCT03746431 | Recruiting | Phase 1/Phase 2 | A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | January 17, 2019 | June 2026 |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT06007690 | Recruiting | Phase 3 | A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | December 6, 2023 | March 1, 2027 |
| NCT03611868 | Recruiting | Phase 1/Phase 2 | A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | August 29, 2018 | March 30, 2025 |
| NCT01438658 | Recruiting | Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma | September 2011 | December 2040 | |
| NCT06075589 | Recruiting | Psychoeducation for Uveal Melanoma | November 7, 2023 | December 1, 2026 | |
| NCT05907954 | Recruiting | Phase 2 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | July 3, 2023 | January 31, 2029 |
| NCT04424719 | Recruiting | N/A | Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) | July 8, 2020 | July 26, 2035 |
| NCT06280040 | Recruiting | Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma | November 23, 2023 | June 30, 2025 | |
| NCT06284512 | Recruiting | Uveal Melanoma - Comparative Study | October 15, 2023 | December 31, 2024 | |
| NCT04588662 | Recruiting | A Prospective Natural History Study in Uveal Melanoma | May 6, 2021 | July 2026 | |
| NCT04728113 | Recruiting | N/A | Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether) | July 16, 2020 | July 20, 2025 |
| NCT04792463 | Recruiting | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | March 3, 2015 | July 1, 2026 | |
| NCT04802876 | Recruiting | Phase 2 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors | April 12, 2021 | March 31, 2027 |
| NCT05004025 | Recruiting | Phase 1 | Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma | February 28, 2022 | August 29, 2025 |
| NCT05077280 | Recruiting | Phase 2 | A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma | September 20, 2021 | March 2026 |
| NCT05377957 | Recruiting | Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients | March 5, 2019 | January 1, 2030 | |
| NCT05496686 | Recruiting | Phase 1 | Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | July 21, 2022 | February 25, 2029 |
| NCT05502900 | Recruiting | Phase 3 | Adjuvant Melatonin for Uveal Melanoma | October 2, 2022 | January 1, 2031 |
| NCT05524935 | Recruiting | Phase 2 | Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | October 11, 2022 | December 2025 |
| NCT05576077 | Recruiting | Phase 1 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | January 17, 2023 | June 30, 2025 |
| NCT05607095 | Recruiting | Phase 1 | Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma | November 1, 2022 | May 1, 2025 |
| NCT05628883 | Recruiting | Phase 1 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | November 22, 2022 | December 31, 2026 |
| NCT05733728 | Recruiting | Retrospective Register for Uveal Melanoma | January 23, 2023 | December 31, 2030 | |
| NCT05889481 | Recruiting | Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma | January 2008 | May 2025 | |
| NCT01471054 | Terminated | Phase 2 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | April 2014 | July 2015 |
| NCT01801358 | Terminated | Phase 1/Phase 2 | A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma | August 2013 | May 2015 |
| NCT00929019 | Terminated | Phase 1/Phase 2 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | June 2009 | April 2016 |
| NCT02029690 | Terminated | Phase 1 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin | April 23, 2014 | June 2020 |
| NCT04589832 | Terminated | Phase 1/Phase 2 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | January 11, 2021 | June 24, 2022 |
| NCT02601378 | Terminated | Phase 1 | A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma. | February 1, 2016 | January 7, 2022 |
| NCT02743611 | Terminated | Phase 1/Phase 2 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | April 14, 2017 | July 19, 2020 |
| NCT02936388 | Unknown status | Phase 2 | Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis | January 2016 | December 2022 |
| NCT03964298 | Unknown status | Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma | November 2016 | December 2019 | |
| NCT00811200 | Unknown status | Phase 2/Phase 3 | Treatment Of Radiation Retinopathy Trial | September 2009 | |
| NCT00540930 | Unknown status | Phase 4 | Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy | April 2007 | April 2009 |
| NCT02379000 | Unknown status | Phase 4 | TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy | January 2015 | July 2018 |
| NCT00459849 | Unknown status | N/A | Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal Melanoma | July 2000 | July 2007 |
| NCT05179174 | Unknown status | The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma | April 20, 2021 | December 2023 | |
| NCT02913417 | Unknown status | Phase 1/Phase 2 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | October 10, 2016 | June 2023 |
| NCT04025424 | Unknown status | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) | June 15, 2019 | December 1, 2023 | |
| NCT01377025 | Unknown status | Phase 2 | A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma | June 2011 | June 2017 |
| NCT00872391 | Unknown status | N/A | Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma | March 2009 | |
| NCT05482074 | Withdrawn | Phase 2 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | October 4, 2022 | May 1, 2027 |
| NCT04184518 | Withdrawn | Phase 2 | Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma | May 2020 | December 2021 |
| NCT03022565 | Withdrawn | Early Phase 1 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | January 2020 | January 29, 2020 |
- Disase is a (Disease Ontology)
- DOID:3479
- Cross Reference ID (Disease Ontology)
- MESH:C536494
- Cross Reference ID (Disease Ontology)
- MIM:155720
- Cross Reference ID (Disease Ontology)
- MIM:606660
- Cross Reference ID (Disease Ontology)
- MIM:606661
- Cross Reference ID (Disease Ontology)
- NCI:C7712
- Cross Reference ID (Disease Ontology)
- ORDO:39044
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0220633
- Exact Synonym (Disease Ontology)
- melanoma of Uvea
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0007716
- OrphaNumber from OrphaNet (Orphanet)
- 39044